AU2007291602B2 - Methods of lowering glucose levels - Google Patents

Methods of lowering glucose levels Download PDF

Info

Publication number
AU2007291602B2
AU2007291602B2 AU2007291602A AU2007291602A AU2007291602B2 AU 2007291602 B2 AU2007291602 B2 AU 2007291602B2 AU 2007291602 A AU2007291602 A AU 2007291602A AU 2007291602 A AU2007291602 A AU 2007291602A AU 2007291602 B2 AU2007291602 B2 AU 2007291602B2
Authority
AU
Australia
Prior art keywords
glucose
ramipril
patient
impaired
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007291602A
Other languages
English (en)
Other versions
AU2007291602A1 (en
Inventor
Hertzel Gerstein
Salim Yusuf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2007291602A1 publication Critical patent/AU2007291602A1/en
Application granted granted Critical
Publication of AU2007291602B2 publication Critical patent/AU2007291602B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
AU2007291602A 2006-08-28 2007-08-14 Methods of lowering glucose levels Ceased AU2007291602B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84085006P 2006-08-28 2006-08-28
US60/840,850 2006-08-28
PCT/EP2007/007160 WO2008025450A1 (en) 2006-08-28 2007-08-14 Methods of lowering glucose levels

Publications (2)

Publication Number Publication Date
AU2007291602A1 AU2007291602A1 (en) 2008-03-06
AU2007291602B2 true AU2007291602B2 (en) 2012-09-06

Family

ID=38578487

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007291602A Ceased AU2007291602B2 (en) 2006-08-28 2007-08-14 Methods of lowering glucose levels

Country Status (12)

Country Link
US (1) US20080188538A1 (enExample)
EP (1) EP2059242A1 (enExample)
JP (1) JP2010501604A (enExample)
KR (1) KR20090042976A (enExample)
CN (1) CN101573110A (enExample)
AU (1) AU2007291602B2 (enExample)
BR (1) BRPI0716411A2 (enExample)
CA (1) CA2661598A1 (enExample)
IL (1) IL197189A0 (enExample)
MX (1) MX2009002091A (enExample)
NO (1) NO20090926L (enExample)
WO (1) WO2008025450A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1437131A1 (en) * 1999-08-27 2004-07-14 Aventis Pharma Deutschland GmbH Use of an ACE inhibitor for the prevention of diabetes in a patient with no preexisting congestive heart failure
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
CA2026686A1 (en) * 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
WO2003032965A2 (en) * 2001-10-17 2003-04-24 King Pharmaceuticals Research And Development, Inc Use of ace inhibitors for reducing type 2 diabetes in high risk patients
CA2458288A1 (en) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1437131A1 (en) * 1999-08-27 2004-07-14 Aventis Pharma Deutschland GmbH Use of an ACE inhibitor for the prevention of diabetes in a patient with no preexisting congestive heart failure
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSUEH, W. CLEVELAND CLINIC JOURNALOF MEDICINE, 2000. Vol.67, no. 11, , pages 807-813 *
YUSUF, S et al. JAMA, 2001. Vol. 286, no. 15, pages 1882-1185 *

Also Published As

Publication number Publication date
IL197189A0 (en) 2009-12-24
JP2010501604A (ja) 2010-01-21
AU2007291602A1 (en) 2008-03-06
CA2661598A1 (en) 2008-03-06
US20080188538A1 (en) 2008-08-07
MX2009002091A (es) 2009-03-09
EP2059242A1 (en) 2009-05-20
CN101573110A (zh) 2009-11-04
KR20090042976A (ko) 2009-05-04
WO2008025450A1 (en) 2008-03-06
NO20090926L (no) 2009-03-27
BRPI0716411A2 (pt) 2013-09-24

Similar Documents

Publication Publication Date Title
CN101534798B (zh) 包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
CN101528204B (zh) 包含血管紧张素Ⅱ受体阻断剂和HMG-CoA还原酶抑制剂的控释复合组合物
JP5241228B2 (ja) 非ステロイド性抗炎症薬、鬱血除去薬および鎮静作用の少ない抗ヒスタミン薬を含む多層錠
CN101528203B (zh) 用于基于择时治疗理论治疗心血管疾病的联合制剂
US20060134213A1 (en) Stabilized ramipril compositions and methods of making
CN103417505B (zh) 具有双相释药行为的石杉碱甲控释制剂及其制备方法
BRPI0708059A2 (pt) formulação de niacina de baixo rubor
CN107157999A (zh) 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
US20030147957A1 (en) Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
WO2008057464A2 (en) Compositions and methods for improving the bioavailability of liothyronine
WO2025051298A1 (zh) 一种盐酸伊伐布雷定缓释片及其制备方法
US20070116762A1 (en) Compositions of stabilized ramipril in combination with another active agent
AU2011339150A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
US20080188538A1 (en) Methods of lowering glucose levels
CN102485228B (zh) 一种药物组合物及其用途
EP1465607B1 (fr) Compositions pharmaceutiques a liberation modifiee
CA2903961A1 (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CA3134786A1 (en) Methods for treating subjects with chronic kidney disease
WO2008134047A1 (en) Methods of treating hypertension
HK1138182A (en) Methods of lowering glucose levels
WO2023175573A1 (en) Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
CN102652747B (zh) 一种用于治疗高血压的复方药物组合物
TW201637650A (zh) 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
TW201103544A (en) Pharmaceutical composition and application thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired